Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced regulatory clearance to finalize acquisition of Kapa Biosystems, Inc. (Kapa), a privately-held company headquartered in Wilmington, Massachusetts, US. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications.
"The completion of this acquisition represents significant advancement in Roche's commitment to develop a differentiated NGS portfolio that will provide our customers with a complete genetic testing solution," said Dan Zabrowski, Head of Roche Tissue Diagnostics and Sequencing Solutions. "Combining Kapa's proprietary protein engineering technology and impressive portfolio of NGS reagents with Roche's offerings and expertise adds to an already robust portfolio of NGS target enrichment products. We look forward to building on our NGS offerings with this unique technology and the combined experience of Kapa and Roche employees."
Trey Foskett, Co-Founder and Chief Technology Officer of Kapa Biosystems remarked, "We are excited to officially become part of the Roche family and look forward to further contributing, on a global scale, to the future of genomics and sequencing. This partnership will accelerate our ability to pioneer new technologies and expand our product portfolio, with the ultimate goal of improving healthcare through more personalized medicine."
Financial terms of the transaction are not disclosed.